TY - JOUR ID - 17601 TI - Planning and management to control and eliminate HTLV-1 infection in Iran JO - Iranian Journal of Basic Medical Sciences JA - IJBMS LA - en SN - 2008-3866 AU - Boostani, Reza AU - Lotfinejad, Nasim AU - Zemorshidi, Fariba AU - Vahidi, Zohreh AU - Rezaee, Seyed Abdolrahim AU - Farid, Reza AU - Rafatpanah, Houshang AD - Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran AD - Department of Research, Faculty of Medicine, Mashhad University of medical sciences, Mashhad, Iran AD - Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran AD - Allergy Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran Y1 - 2021 PY - 2021 VL - 24 IS - 3 SP - 264 EP - 266 KW - ATL HAM/TSP HTLV KW - 1 Prevention Treatments DO - 10.22038/ijbms.2021.50803.11562 N2 - Prevention and treatment of the Human T-cell leukemia virus, type 1 (HTLV-1) which was discovered nearly 40 years ago, still remain challenging. The reported high prevalence of HTLV-1 in some countries around the world triggered an open letter to the World Health Organization (WHO), urging action against HTLV-1 infection in 2018. This highlights the importance of virus elimination strategies to eradicate HTLV-1 infection. In Iran, we have documented our experiences with the virus in order to achieve and promote the possible ways to manage, control, and eliminate HTLV-1. Although there has been considerable progress apropos of HTLV-1, a series of additional challenges need to be tackled to control HTLV-1 infection in Iran.  UR - https://ijbms.mums.ac.ir/article_17601.html L1 - https://ijbms.mums.ac.ir/article_17601_299e308ee1eb3c7760033c0139df391f.pdf ER -